Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Radiogallium-labeled gadolinium-porphyrin complex: A new agent for imaging and photodynamic therapy

Document Type : Original Article

Authors
Ali Arjmandpour 1, 2
Yousef Fazaeli 1
Seyed Mohammad Mahdi Abtahi 2
Parviz Ashtari 1
Saeed Karampour 1
Gholamreza Shahhosseini 1
Shahzad Feizi 1
1 Radiation Application Research School, Nuclear Science and Technology Research Institute, Karaj, Iran
2 Physics Department, Faculty of Basic Sciences, Imam Khomeini International University, Qazvin, Iran
10.22034/irjnm.2022.40037
Abstract
Introduction: Metalloporphyrin-based contrast agents can improve probe functionality such as biocompatibility, prolonging presence in blood, and specific tumor accumulation. Herein, we report synthesis, structural characteristics, quality control, and nuclear imaging of new metalloporphyrin-based contrast agents.
Methods: To combine photodynamic therapy (PDT), magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computerized tomography (SPECT), Gadolinium-proto porphyrin IX complex was synthesized via direct complexation method, then the metalloporphyrin (MP) was labeled with gallium-67 and gallium-68 in separated runs. In-vivo biodistribution studies were performed in mice bearing breast tumor (4T1 mouse mammary tumor cell line) and normal rats (for better visualization).
Results: Adsorption of the labeled compound into the tumor (ID/g % up to 4.6%), despite the small size of the tumor, had an upward trend at all times, and high and fast (less than 45 min) uptake of radiotracer in cancerous tumors was observed.  
Conclusion:  Fast and high tumor uptake revealed that this radiotracer could potentially be used as a theranostic agent.
Keywords
Metalloporphyrin
68&67Ga, Breast tumor, Theranostic, PDT
Subjects
  1. Tong KC, Hu D, Wan PK, Lok CN, Che CM. Anticancer Gold(III) compounds with porphyrin or N-heterocyclic carbene ligands. Front Chem. 2020 Nov 6;8:587207.
  2. Janas K, Boniewska-Bernacka E, Dyrda G, Słota R. Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer. Bioorg Med Chem. 2021 Jan 15;30:115926.
  3. Fazaeli Y, Hosseini MA, Shahabinia F, Feizi S. 68Ga-5, 10, 15, 20-Tetrakis (2, 4, 6-trimethoxy phenyl) porphyrin: a novel radio-labeled porphyrin complex for positron emission tomography. J Radioanal Nucl Chem. 2019 Apr;320(1):201-7.
  4. Ethirajan M, Patel NJ, Pandey RK. Chapter 19: Porphyrin-based multifunctional agents for tumor-imaging and photodynamic therapy (PDT).  Kadish KM, Smith KM,   Guilard R, editors. Handbook of porphyrin science volume 4. Singapore: World Scientific Publishing Company; 2010. p. 249-323.
  5. Deda DK, Iglesias BA, Alves E, Araki K, Garcia CRS. Porphyrin derivative nanoformulations for therapy and antiparasitic agents. Molecules. 2020 Apr 29;25(9):2080.
  6. Yan L, Miller J, Yuan M, Liu JF, Busch TM, Tsourkas A, Cheng Z. Improved photodynamic therapy efficacy of protoporphyrin IX-loaded polymeric micelles using erlotinib pretreatment. Biomacromolecules. 2017 Jun 12;18(6):1836-1844.
  7. Morales-de-Echegaray AV, Maltais TR, Lin L, Younis W, Kadasala NR, Seleem MN, Wei A. Rapid uptake and photodynamic inactivation of staphylococci by Ga(III)-protoporphyrin IX. ACS Infect Dis. 2018 Nov 9;4(11):1564-1573.
  8. Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol. 2008 Mar;10(3):148-54.
  9. Bohle DS, Dodd EL. [Gallium (III) protoporphyrin IX] 2: a soluble diamagnetic model for malaria pigment. Inorg Chem. 2012 Apr 16;51(8):4411-3.
  10. Bohle DS, Dodd EL, Pinter TB, Stillman MJ. Soluble diamagnetic model for malaria pigment: coordination chemistry of gallium(III)protoporphyrin-IX. Inorg Chem. 2012 Oct 15;51(20):10747-61.
  11. Pinter TB, Dodd EL, Bohle DS, Stillman MJ. Spectroscopic and theoretical studies of Ga(III)protoporphyrin-IX and its reactions with myoglobin. Inorg Chem. 2012 Mar 19;51(6):3743-53.
  12. Chang D, Garcia RA, Akers KS, Mende K, Murray CK, Wenke JC, Sanchez CJ. Activity of Gallium meso- and protoporphyrin IX against biofilms of multidrug-resistant acinetobacter baumannii isolates. Pharmaceuticals (Basel). 2016 Mar 17;9(1):16.
  13. Stojiljkovic I, Kumar V, Srinivasan N. Non-iron metalloporphyrins: potent antibacterial compounds that exploit haem/Hb uptake systems of pathogenic bacteria. Mol Microbiol. 1999 Jan;31(2):429-42.
  14. Hijazi S, Visca P, Frangipani E. Gallium-protoporphyrin IX Inhibits Pseudomonas aeruginosa growth by targeting cytochromes. Front Cell Infect Microbiol. 2017 Jan 26;7:12.
  15. Espinosa-Cano E, Palao-Suay R, Aguilar MR, Vázquez B, Román JS. Polymeric nanoparticles for cancer therapy and bioimaging. Gonçalves G, Tobias G, editors. Nanooncology. Nanomedicine and Nanotoxicology. 1st ed. Switzerland: Springer Cham; 2018. p.  137-172
  16. Zang L, Zhao H, Hua J, Qin F, Zheng Y, Zhang Z, Cao W. Water-soluble gadolinium porphyrin as a multifunctional theranostic agent: Phosphorescence-based oxygen sensing and photosensitivity. Dyes Pigm. 2017 Jul 1;142:465-71.
  17. Samkoe KS, Gibbs-Strauss SL, Yang HH, Khan Hekmatyar S, Jack Hoopes P, O'Hara JA, Kauppinen RA, Pogue BW. Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy. J Biomed Opt. 2011 Sep;16(9):096008.
  18. Guleria M, Das T, Vats K, Amirdhanayagam J, Mathur A, Sarma HD, Dash A. Preparation and evaluation of 99mTc-labeled porphyrin complexes prepared using PNP and HYNIC cores: studying the effects of core selection on pharmacokinetics and tumor uptake in a mouse model. Medchemcomm. 2019 Feb 22;10(4):606-615.
  19. Entract GM, Bryden F, Domarkas J, Savoie H, Allott L, Archibald SJ, Cawthorne C, Boyle RW. Development of PDT/PET theranostics: synthesis and biological evaluation of an (18)F-radiolabeled water-soluble porphyrin. Mol Pharm. 2015 Dec 7;12(12):4414-23.
  20. Hervella P, Dam JH, Thisgaard H, Baun C, Olsen BB, Høilund-Carlsen PF, Needham D. Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. J Control Release. 2018 Dec 10;291:11-25.
  21. Fazaeli Y, Feizi S, Jalilian AR, Hejrani A. Grafting of [(64)Cu]-TPPF20 porphyrin complex on Functionalized nano-porous MCM-41 silica as a potential cancer imaging agent. Appl Radiat Isot. 2016 Jun;112:13-9.
  22. Fazaeli Y, Jalilian AR, Amini MM, Ardaneh K, Rahiminejad A, Bolourinovin F, Moradkhani S, Majdabadi A. Development of a (68)Ga-fluorinated porphyrin complex as a possible PET imaging agent. Nucl Med Mol Imaging. 2012 Mar;46(1):20-6.
  23. Fazaeli Y, Jalilian AR, Rezaee F, Firouzyar T, Moradkhani S, Bagheri A, Majdabadi A. Development of radiolabeled radachlorin complex as a possible tumor targeting agent. J Radioanal  Nucl Chem. 2015 Mar;303(3):1695-701.
  24. Fazaeli Y, Shanehsazzadeh S, Lahooti A, Feizi S, Jalilian A. Preclinical dosimetric estimation of [111In] 5, 10, 15, 20-tetra phenyl porphyrin complex as a possible imaging/PDT agent. Radiochim Acta. 2016 May 28;104(5):327-36.
  25. Fazaeli Y, Jalilian AR, Khalaj A. Development of a new radiogallium porphyrin complex as a possible tumor imaging agent. Int J Nucl Med Res. 2015 Mar 20;2(1):7-15.
  26. Fazaeli Y, Jalilian AR, Feizi S, Shadanpour N. Development of a radiothallium (III) labeld porphyrin complex as a potential imaging agent. Radiochim Acta. 2013 Dec 1;101(12):795-800.
  27. Eguchi K, Nakamura H, Zhou JR, Jun F, Yokomizo K, Haratake MJ. Hyaluronic acid-zinc protoporphyrin conjugates for photodynamic antitumor therapy. J Nanomed Nanotechnol. 2007;8 (2):100400.
  28. Zhu B, Liu Q, Wang Y, Wang X, Wang P, Zhang L, Su S. Comparison of accumulation, subcellular location, and sonodynamic cytotoxicity between hematoporphyrin and protoporphyrin IX in L1210 cells. Chemotherapy. 2010;56(5):403-10.
  29. Lv Y, Zheng J, Zhou Q, Jia L, Wang C, Liu N, Zhao H, Ji H, Li B, Cao W. Antiproliferative and apoptosis-inducing effect of exo-protoporphyrin IX based sonodynamic therapy on human oral squamous cell carcinoma. Sci Rep. 2017 Jan 19;7:40967.
  30. Tomaszewski MR, Gonzalez IQ, O'Connor JP, Abeyakoon O, Parker GJ, Williams KJ, Gilbert FJ, Bohndiek SE. Oxygen enhanced optoacoustic tomography (OE-OT) reveals vascular dynamics in murine models of prostate cancer. Theranostics. 2017 Jul 8;7(11):2900-2913.
  31. Vahidfar N, Jalilian AR, Fazaeli Y, Aghanejad A, Bahrami-Samani A, Alirezapour B, Erfani M, Beiki D, Khalaj A. Development of radiolanthanide labeled porphyrin complexes as possible therapeutic agents in beast carcinoma xenografts. Radiochim Acta. 2014 Jul 28;102(7):659-68.
  32. Agondanou JH, Spyroulias GA, Purans J, Tsikalas G, Souleau C, Coutsolelos AG, Bénazeth S. XAFS study of gadolinium and samarium bisporphyrinate complexes. Inorg Chem. 2001 Nov 19;40(24):6088-96.
  33. Bulach V, Sguerra F, Hosseini MW. Porphyrin lanthanide complexes for NIR emission. Coord Chem Rev. 2012 Aug 1;256(15-16):1468-78.